Predictors of Thromboembolic Events in Patients with Lung Cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00084851" target="_blank" >RIV/00216224:14110/15:00084851 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Predictors of Thromboembolic Events in Patients with Lung Cancer

Popis výsledku v původním jazyce

Background: Patients with lung cancer experience elevated risk of venous thromboembolism Prothrombotic factors in lung cancer include the ability of tumour cells to produce and secrete procoagulant substances and inflammatory cytokines, and the physicalinteraction between tumour cell and blood. Other mechanisms of thrombus promotion in malignancy include surgery, metastatic disease and use of chemotherapeutic drugs in combination with novel targeted drugs, such as antiangiogenic agents. Cancer patientswith thrombosis have a shorter life expectancy than cancer patients without this complication. The occurrence of VTE worsens the quality of life and may delay, interrupt, or completely halt the cancer therapy. Conclusion: The incidence of serious thromboembolic events (8.4%) in our group of lung cancer patients was high, especially in patients with adenocarcinoma, advanced-stage disease, and in patiens on cancer treatment.

Název v anglickém jazyce

Predictors of Thromboembolic Events in Patients with Lung Cancer

Popis výsledku anglicky

Background: Patients with lung cancer experience elevated risk of venous thromboembolism Prothrombotic factors in lung cancer include the ability of tumour cells to produce and secrete procoagulant substances and inflammatory cytokines, and the physicalinteraction between tumour cell and blood. Other mechanisms of thrombus promotion in malignancy include surgery, metastatic disease and use of chemotherapeutic drugs in combination with novel targeted drugs, such as antiangiogenic agents. Cancer patientswith thrombosis have a shorter life expectancy than cancer patients without this complication. The occurrence of VTE worsens the quality of life and may delay, interrupt, or completely halt the cancer therapy. Conclusion: The incidence of serious thromboembolic events (8.4%) in our group of lung cancer patients was high, especially in patients with adenocarcinoma, advanced-stage disease, and in patiens on cancer treatment.

Druh

O - Ostatní výsledky

CEP obor

FC - Pneumologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů